

DAFTAR PUSTAKA

- Abduljabbar, R., Al-Kaabi, M. M., Negm, O. H., Jerjees, D., Muftah, A. A., Mukherjee, A. *et al.* (2015). Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. *Breast Cancer Res Treat.*, 150: 511–522. DOI:10.1007/s10549-015-3348-9.
- Alessi, M.C., Juhan-Vague, I. (2008). Metabolic syndrome, haemostatic, and thrombosis. *Thromb Haemost.*, 99:995-1000.
- Alikhani, N., Fergusson, R.D., Novosyadlyy, R. (2013). Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse models. *Oncogene* 32:961-967.
- Amini, S., Abak, A., Estiar, M. A., Montazeri, V., Abhari, A., Sakhinia, E. (2018). Expression Analysis of MicroRNA-222 in Breast Cancer. *Clinical laboratory*, 64(4), 491–496. DOI: 10.7754/Clin.Lab.2017.171002
- Arner, E., Mejhert, N., Kulyté, A., Balwierz, P. J., Pachkov, M., Cormont, M. *et al.* (2012). Adipose tissue microRNAs as regulators of CCL2 production in human obesity. *Diabetes*, 61(8), 1986–1993. DOI: 10.2337/db11-1508
- Arner, P., Kulyte, A. (2015). MicroRNA regulatory networks in human adipose tissue and obesity. *Nat.Rev. Endocrinol.*, 11: 276-288.
- Berrino, F., Villarini, A., Traina, A., Bonanni, B., Panico, S., Mano, M.P. (2014). Metabolic syndrome and breast cancer prognosis. *Breast Cancer Res Treat.*, 147:159-165.
- Bertoli, G., Cava, C., Castiglioni, I. (2015). MicroRNAs: New Biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. *Theranostics* 5:1122-1143.
- Bitzur, R., Brenner, R., Maor, E., Antebi, M., Ziv-Baran, T., Segev, S. (2016). Metabolic syndrome, obesity, and risk of cancer development. *Eur J Intern Med.*, 34:89-93.
- Borugian, M.J., Sheps, S.B., Kim-Sing, C., Olivotto, I.A., Patten, C.V., Dunn, B.P. *et al.* (2003) Waist-hip ratio and breast cancer mortality. *Am J Epidemiol.*, 158:963-968.
- Braun, S., Bitton-Worm, K., LeRoith, D. (2011). The Link between the metabolic syndrome and cancer. *Int J Biol Sci.*, 7:1003-1015.
- Buono, G., Crispo, A., Giuliano, M., De Angelis, C., Schettini, F., Forestieri, V. *et al.* (2020). Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. *Breast Cancer Research and Treatment*. 182:401-409.
- Buttros Dde, A., Nahas, E.A., Vespoli Hde, L., Uemura, G., de Almeida Bda, R., Nahas-Neto, J. (2013). Risk of metabolic syndrome in post-menopausal breast cancer survivors. *Menopause* 20:448-454.

Callip, G.S., Malone, K.E., Gralow, J.R. (2014). Metabolic syndrome and outcome following early- stage breast cancer. *Breast Cancer Res Treat.*, 148:363-377.

Capobianco, V., Nardelli, C., Ferrigno, M., Iaffaldano, L., Pitone, V., Forestieri, P. *et al.* (2012). miRNA and protein expression profiles of visceral adipose tissue reveal miR-141/YWHAG and miR-520e/RAB11A as two potential miRNA/protein target pairs associated with severe obesity. *J Proteome Res.* Jun 1;11:3358-69. DOI: 10.1021/pr300152z.

Cecchini, R.S., Swain, S.M., Costantino, J.P., Rastogi, P., Jeong, J-H., Anderson, S.J. *et al.* (2016) Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology/NSABP B-30, B-31, B-34, and B-38. *Canc Epidemiol Biomarkers Prev.*, 25:51e9.

Chan, D., Vieira, A., Aune, D., Bandera, E., Greenwood, D., McTierman, A. *et al.* (2014). Body mass index and survival in women with breast cancer – systemic literature review and meta-analysis of 82 follow-up studies. *Annals of Oncology.* 25: 1901-1914.

Chen, L., Dai, Y.M., Ji, C.B., Yang, L., Shi, C.M., Xu, G.F. *et al.* (2014). MiR-146b is a regulator of human visceral preadipocyte proliferation and differentiation and its expression is altered in human obesity. *Mol Cell Endocrinol.*, 5;393:65-74. DOI: 10.1016/j.mce.2014.05.022

Chen, W.W., Shao, Y.Y., Shau, W.Y. (2012). The impact of diabetes mellitus on prognosis of early breast cancer in Asia. *Oncologist.*17:485-491

Chen, W.X., Hu, Q., Qiu, M.T., Zhong, S.L., Xu, J.J., Tang, J.H. *et al.* (2013). miR-221/222: promising biomarkers for breast cancer. *Tumour Biol.*, 34: 1361-1370.

Chen, Y., Liu, L., Zhou, Q., Imam, M.U., Cai, J., Wang, Y. *et al.* (2017). Body mass index had different effects on premenopausal and post menopausal breast cancer risk: a dose-response meta-analysis with 3,318,796 subjects from 31 cohort studies. *BMC Public Health.* 17: 936 DOI: 10.1186/s12889-017-4953-9.

Chou, W.W., Wang, Y.T., Liao, Y.C., Chuang, S.C., Wang, S.N., Juo, S.H. (2013). Decreased microRNA-221 is associated with high levels of TNF- α in human adipose tissue-derived mesenchymal stem cells from obese woman. *Cell Physiol Biochem.*, 32:127-137. DOI: 10.1159/000350131.

Cianfrocca, M., Goldstein, L.J. (2004). Prognostic and predictive factors in early-stage breast cancer. *The Oncologist.* 9:606-61.

Cleveland, R.J., North, K.E., Stevens, J. (2012). The association of diabetes with breast cancer incidence and mortality in Long Island Breast Cancer Study Project. *Cancer Causes Control* 23:1193-1203.



UNIVERSITAS
GADJAH MADA

**HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA
SUB-TIPE MOLEKULER
HR+/HER2- NON-METASTATIK** Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin,
miR-222-3p, dan miR-143-3p

KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM

Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Coates. A.S., Winer, E.P., Goldhirsch, A., Gelber, R.D., Gnani, M., Piccart-Gebhart, M. (2015). Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. *Ann Oncol.*, 26:1533-1546.

Collares, R.V.A, Salgado, W., Tirapelli, D.P.C., Santos, J.S. (2014). The Expression of LEP, LEPR, IGF1 and IL10 in Obesity and the Relationship with microRNAs. *Plos One.* 9(4): e93512. DOI: 10.1371/journal.pone.0093512.

Deiuliis, J.A. (2016). MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. *Int J Obes.*, 40:88-101.

Deng, L., Lei, Q., Wang, Y., Wang, Z., Xie, G., Zhong, X. *et al.* (2017). Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negatives breast cancer patients and associated with poor prognosis. *Oncotarget* 108712-108725.

Dentelli, P., Traversa, M., Russo, A., Togliatto, G., Olgasi C., Marvh, C. *et al.* (2014). MiR-221/222 control luminal breast cancer progression by regulating different targets. *Cell Cycle.* 13: 1811-1826.

Diawara, M.R., Hue, C., Wilder, S.P., Venteclef, N., Aron-Wisnewsky, J., Scott, J. *et al.* (2014). Adaptive expression of microRNA-125a in adipose tissue in response to obesity in mice and men. *PLoS One.* 27;9:e91375. DOI: 10.1371/journal.pone.0091375.

Dibaba, D.T., Ogunsina, K., Braithwaite, D., Akinyemiju, T. (2019). Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype. *Breast Cancer Res Treat.*, 174: 209-218.

Dieli-Conwright, C.M., Wong, L., Waliyany, S., Bernstein, L., Salehian, B., Mortimer, J.E. (2016). An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. *Cancer* 122:2646-2653.

Dong T. (2013). Anticancer activities of PPAR γ in breast cancer are context-dependent. *Am J Pathol.*;182:1–4.

Esposito, K., Chiodini, P., Calao, A., Lenzi, A., Giugliano D. (2012). Metabolic syndrome and risk of Cancer. *Diabetes Care* 35:2402-2411

Esposito, K., Chiodini, P., Capuano, A., Bellastella, G., Majorino, M.I., Rafaniello, C. (2013). Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis *Menopause* 20(12):1301-1309.

Oh, S. W. *et al.* (2011) ‘Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study’, *Breast Cancer Research*, 13(2). doi: 10.1186/bcr2856.



UNIVERSITAS
GADJAH MADA

HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA SUB-TIPE MOLEKULER HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin, miR-222-3p, dan miR-143-3p
KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM
Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Oyamada, M., Takebe, K., Oyamada, Y. 2013. Regulation of connexin expression by transcription factors and epigenetic mechanisms. *BBA-Biomembranes*. 1823: 118-113.

Falkenberg, N., Anastasov, N., Rappl, K., Braselmann, H., Auer, G., Walch, A. *et al.* (2013). MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. *Br J Cancer*, 109(10), 2714–2723. DOI: 10.1038/bjc.2013.625

Fu X., Li Y., Alvero A., Li J., Wu Q., Xiao Q. *et al.* (2016). MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. *Oncotarget*. 7: 80633-80654

Gan,R., Yang, Y., Yang. X., Zhao, L., Lu, J., Meng, H. (2014). Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMPS3. *Cancer Gene Therapy* 21: 290-296.

Garafalo, C., Koda, M., Cascio, S. (2006). Increase expression of leptin and leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. *Clin Can Research* 12 (5);1-7

Gennari, A., Amadori, D., Scarpi, E. *et al.* (2016). Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. *Breast Cancer Res Treat.*, 159, 79–86. DOI:10.1007/s10549-016-3923-8

GLOBOCAN 2017 Cancer Fact Sheet. (2017). *Braz J Med Biol Res.*, 50(8): e5891. DOI: 10.1590/1414-431X20175891

Grundny, S.M. (1998). Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. *Am J Cardiol.*, 81:18B-25B

Grundny, S.M. (2007). Metabolic syndrome: A multiplex cardiovascular risk factor. *J Clin Endocrinol Metab.* 92:399-404

Grundny, S.M. (2015). Adipose tissue and metabolic syndrome: too much, too little, or neither. *Eur J Clin Invest.* 45:1209-1217

Grundny, M.S. (2016). Metabolic syndrome update. *Trends Cardiovasc. Med* 26:364-373

Gu, L., Wang, C., Cao, C., Chai, L., Li, D., Zheng, Y. 2019. Association of serum leptin with breast cancer.A meta-analysis. *Medicine*.98:5. DOI: 10.1097/MD 014094

Gunter, M.J., Xie, X., Xue, X., Kabat, G.C., Rohan, T.E., Wassertheil-Smoller, S. (2015). Breast cancer risk in metabolically normal but overweight postmenopausal women. *Cancer Res.*, 75:270-274.

Han, S., Kim, H.J., Gwak, J.M., Kim, M., Chung, Y.R., Park, S.Y. (2017). MicroRNA-222 expression as a predictive marker for tumor progression in hormone receptor-positive breast cancer. *J Breast Cancer* 20:35-44.



UNIVERSITAS
GADJAH MADA

HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA SUB-TIPE MOLEKULER HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin, miR-222-3p, dan miR-143-3p
KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM
Universitas Gadjah Mada, 2021 | Diunduh dari <http://eud.repository.ugm.ac.id/>

Han, X., Li, Q., Liu, C., Wang, C., Li, Y. (2019). Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer. *J Cell Biochem.*120:12966-12976.

Haque, I., Ghosh, A., Acup, S., Banerjee, S., Dhar, K., Ray, A. 2018. Leptin-induced ER- α -positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway. *BMC Cancer* 18:99. DOI 10.1186/s12885-018-3993-6.

Harrell, J.C., Shroka, T.M., Jacobsen, B.M. 2017. Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer. *Oncogenesis.*6: 396

Healy, L.A., Ryan, A.M., Carroll, P., Ennis, D., Crowley, V., Boyle, T., Kennedy, M.J., Connolly, E., Reynolds, J.V. (2010). Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. *Clin. Oncol. R. Coll. Radiol.* DOI 10.1016/j.clon.2010.02.001.

Heneghan, H. M., Miller, N., McAnena, O. J., O'Brien, T., Kerin, M. J. (2011). Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. *J. Clin. Endocrinol. Metab.* 96, E846–E850.

Hilton, C., Neville, MU, Karpe F. (2012). MicroRNAs in adipose tissue: their role in adipogenesis and obesity. *Int J Obes:*1-8.

Hoppe, R., Fan, P., Buttner, F. (2016). Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. *Oncotarget* 7:71235-71254.

Hoy, A.J., Balaban, S., Saunders, D.N. (2017). Adipocyte-tumor cell metabolic crosstalk in breast cancer. *Trends Mol Med* 23:381-392.

Hwang, M.S., Yu, N., Stinson, S.Y. (2013). miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. *PlosOne* 8: e66502-DOI: 10.1371/journal.pone.0066502.

Jeong, Y.J., Bong, J.G., Park, S.H., Choi, J.H., Oh, J.H. (2011). Expression of Leptin, Leptin Receptor, Adiponectin, and Adiponectin Receptor in Ductal Carcinoma in Situ and Invasive Breast Cancer. *J Breast Cancer* 14; 96-103.

Jiang, F., Zhang, L., Liu, Y., Zhou, Y., Wang, H. (2020). Overexpression of miR-331 indicates poor prognosis and promotes progression of breast cancer. *Oncol Res Treat.*, 43:441–448. DOI:10.1159/000508792

Jiang, Y., Zou, L., Zhang, C., He, S., Cheng, C., Xu, J. *et al.* (2009). PPAR gamma and Wnt/beta-Catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations. *J Cancer Res Clin Onco.*1 135: 1551–1559. DOI:10.1007/s00432-0090602 -8

Jiralerspong S, Goodwin PJ. (2016). Obesity and breast cancer prognosis: evidence, challenges, and opportunities. *J Clin Oncol.* 34:4203e16



UNIVERSITAS
GADJAH MADA

HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA SUB-TIPE MOLEKULER HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin, miR-222-3p, dan miR-143-3p
KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM
Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Johannessen, C., Moi, L., Kiselev, Y. (2017). Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. *PlosOne* 12(10): e0186658. DOI:10.1373/journal.pone.0186658

Kabat, G., Kim, M.Y., Lee, J.S., Ho, G.Y., Going, S.G., Beebe-Dimmer, J. (2017). Metabolic obesity phenotype and risk of breast cancer in post-menopausal women. *American Association of Cancer Research* DOI: 10.1158/1055-9965.EPI-17-0495

Karkeni, E., Astier, J., Tourniaire, F., El Abed, M., Romier, B., Gouranton, E. *et al.* (2016). Obesity-associated Inflammation Induces microRNA-155 Expression in Adipocytes and Adipose Tissue: Outcome on Adipocyte Function. *JCEM* 101:1615-1626

Kasiappan, R. and Rajarajan, D. (2017). Role of MicroRNA regulation in obesity-associated breast cancer: Nutritional perspectives. *Adv Nutr.*, 8(6):868-888 DOI:10.395/an/117.015800

Keller, P., Gburcik, V., Petrovic, N., Gallagher, I.J., Nedergaard, J., Cannon, B. *et al.* (2011). Gene-chip studies of adipogenesis-regulated microRNAs in mouse primary adipocytes and human obesity. *BMC Endocr Disord.* 22; 11:7. DOI: 10.1186/1472-6823-11-7.

Khabaz, M. N., Abdelrahman, A., Butt, N., Damnhory, L., Elshal, M., Aldahlawi, A. M, *et al.* (2017). Immunohistochemical staining of leptin is associated with grade, stage, lymph node involvement, recurrence, and hormone receptor phenotypes in breast cancer. *BMC women's health*, 17(1), 105. <https://doi.org/10.1186/s12905-017-0459-y>

Khaidakov, M., Mehta, J.L. (2012). Oxidized LDL Triggers Pro-Oncogenic Signaling in Human Breast Mammary Epithelial Cells Partly via Stimulation of MiR-21. *PLoS ONE*; 7(10): e46973. DOI:10.1371/journal.pone.0046973

Khalighfard, S., Alizadeh, A. M., Irani, S., Omranipour, R. (2018). Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. *Scientific reports.* 8(1):17981. DOI: 10.1038/s41598-018-36321-3.

Kiew, S.J., Islam, T., Taib, N.A., Majid, H. (2018). The prevalence of metabolic syndrome among newly diagnosis Malaysian Breast Cancer patients. *JCO Global Oncology.* 4: supp.2 DOI:10.1200/jgo.18.46700.

Kim, Y., Kim, Y-S., Lee, J.J., Seo, J., Kim, Y-W., Koh, S.W. (2006). Effects of the Expression of Leptin and Leptin Receptor (OBR) on the Prognosis of Early-stage Breast Cancers. *Cancer Res Treat.* 38:126-132.

Kim, Y.J., Hwang, S.J., Bae, Y.C., Jung, J.S. (2009). MiR-21 regulates adipogenic differentiation through the modulation of TGF-beta signaling in mesenchymal stem cells derived from human adipose tissue. *Stem Cells* 27: 3093–3102.

Kim, Y.J., Hwang, S.H., Cho, H.H., Shin, K.K., Bae, Y.C., Jung, J.S. (2012). MicroRNA-21 regulates the proliferation of human adipose tissue derived mesenchymal stem cells and high-fat



UNIVERSITAS
GADJAH MADA

HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA SUB-TIPE MOLEKULER HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin, miR-222-3p, dan miR-143-3p
KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM
Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

diet-induced obesity alters microRNA-21 expression in white adipose tissues. *J Cell Physiol* 227: 183–193.

Kilic, I. D., Dodurga, Y., Uludag, B., Alihanoglu, Y. I. (2015). MicroRNA -143 and -223 in obesity. *Gene* 560:140–142.

Kong, Y., Dong, Q., Ji, H. Sang, M., Ding, Y., Zhao, M. (2019). The effect of leptin and leptin receptor expression on the efficacy of neoadjuvant chemotherapy in breast cancer. *Med Sci Monit.* 25: 3005-3013.

Kou, F., Wu, L., Ren, X., Yang, L. 2020. Chromosome abnormalities: new insights into their clinical significance in cancer. *Mol Ther Oncolytics.* 17:562-570. DOI: 10.1016/j.omto.2020.05.010

Kwan, M.L., John, E.M., Caan, B.J., Lee, V.S., Bernstein, I, Cheng, I. (2014). Obesity and mortality after breast cancer by race/ethnicity: the Californian breast cancer survivorship consortium. *Am J Epidemiol.*179:95–111.

Lennon, H., Sperrin, M., Badrick, E., Renehan, A.G. (2016). The obesity paradox in cancer: a review. *Curr Oncol Rep.*18:56 DOI:10.1007/s11912-016-0539-4.

Li, M.Y., Pan, S.R., Qiu, A.Y. (2016). Roles of microRNA-221/222 in type 2 diabetic patients with post-menopausal breast cancer. *Genet and Mol Res.* 15:2. DOI: 10.4238/gmr.15027259.

Li, P., Wang, T., Zeng, C., Yang, M., Li, G., Han, J. (2020). Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies. *Diabetology & Metabolic Syndrome* 12. DOI:10.1186/s13098-019-0514-y.

Li, Z., Sun, B, Gong, T., Birnbaumer, L., Zhou, X., Chu, W. (2019). GNAI1 and GNAI3 reduces colitis-associated tumorigenesis in mice by blocking IL6 signaling and down-regulating expression of GNAI2. *Gastroenterology* [https://DOI.org/10/1053/J.hastro .2019.02.040](https://doi.org/10.1053/J.hastro.2019.02.040).

Liang, X., Wang, S., Wang X. (2018). Leptin promotes the growth of breast cancer by upregulating the Wnt/ β -catenin pathway. *Exp Ther Med.*, 16:767-771.

Liang, Y., Lin, H., Dou, X., Chen, M., Wei, X., Zhang, Y. *et al.* (2018). Mir-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines. *npj Breast Cancer* 4:20.

Lin, T. C., Huang, K. W., Liu, C. W., Chang, Y. C., Lin, W. M., Yang, T. Y., Hsiao, M. (2018). Leptin signaling axis specifically associates with clinical prognosis and is multifunctional in regulating cancer progression. *Oncotarget*, 9(24), 17210–17219. DOI:10.18632/oncotarget.24966

Liu, J., Grundy, S.M., Wang, W., Smith, S.C., Vega, G.L., Wu, Z. (2006). Ethnic-specific criteria for metabolic syndrome. *Diabetes Care* 29:1414-1416.



UNIVERSITAS
GADJAH MADA

**HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA
SUB-TIPE MOLEKULER**

HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin,
miR-222-3p, dan miR-143-3p

KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM

Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Liu, P., Sun, M., Jiang, W., Zhao, J., Liang, C., Zhang, H. (2016). Identification of targets of miRNA-221 and miRNA-222 in fulvestrant-resistant breast cancer. *Oncology Letters* 12:3882-3888.

Llanos, A. A. M., Lin, Y., Chen, W., Yao, S., Norin, J., Chekmareva, M.A. *et al.* (2020) Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: Associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype, *Breast Cancer Res.* DOI:10.1186/s13058-020-1256-3.

Lowery, A. J., Miller, N., Devaney, A., McNeill, R. E., Davoren, P. A., Lemetre, C. *et al.* (2009). MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. *Breast Cancer Res.*, 11, R27. DOI:10.1186/bcr2257.

Lu K, Wang J, Song Y, Zhao S, Liu H, Tang D. *et al.* (2015). miRNA-24-3p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting p27Kip1 *Oncology Report.* 34:995-1002

Luengo-Gil, G., García-Martínez, E., Chaves-Benito, A., Conesa-Zamora, P., Navarro-Manzano, E., González-Billalabeitia, E., *et al.* (2019). Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. *Cell Oncol* (Dord). 42; 627–644. DOI:10.1007/s13402-019-00450-2.

Luque, R.M., Lopez-Sanchez, L.M., Villa-Osaba, A., Luque, I.M., Santos-Romero, A.L., Yuberro-Serrano, E.M. (2017). Breast cancer is associated to impaired glucose/insulin homeostasis in premenopausal obese/overweight patients. *Oncotarget* 8:81462-81474.

Ma, J. and Zhou, Z. (2019). Downregulation of miR-302b is associated with poor prognosis and tumor progression of breast cancer. *Breast Cancer.* DOI: 10.1007/s1282-019-01022-w

Martinelli, R., Nardelli, C., Pilone, V., Buonomo, T., Liguori, R., Castanò, I. *et al.* (2010). miR-519d overexpression is associated with human obesity. *Obesity (Silver Spring)* 18:2170-6. DOI: 10.1038/oby.2009.474.

McTiernan, A. (2003). Behavioral risk factors in breast cancer: can risk be modified? *The Oncologist* 8: 326–334

Meerson, A., Traurig, M., Ossowski, V., Fleming, J.M., Mullins, M., Baier, L.J. (2013). Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF- α . *Diabetologia.*56:1971-1979. DOI:10.1007/s00125-013-2950-9.

Miller, T.E., Goshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C.L. (2008). MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27^{Kip1}. *The Journal of Biological Chemistry* 283:29897-29903.

Moy, F.M., Bulgiba, A. (2010). The modified NCEP ATP III criteria maybe better than the IDF criteria in diagnosing metabolic syndrome among Malays in Kuala Lumpur. *BMC Public Health* 10:678-684.



UNIVERSITAS
GADJAH MADA

**HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA
SUB-TIPE MOLEKULER**

HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin,
miR-222-3p, dan miR-143-3p

KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM

Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Ng, E.K., Li, R., Shin, V.Y., Siu, J.M., Ma, E.S., Kwong, A. (2014). MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. *Tumour Biol.* 35:2591-8.

Nichols, H.B., Trentham-Dietz, A., Egan, K.M. (2009). Body mass index before and after breast cancer diagnosis: association with all-cause, breast cancer and cardiovascular disease mortality. *Cancer Epidemiol. Biomark. Prev* 18:1403-1409.

Nigro, E., Scudiero, O., Monaco, L. (2014). New insight into adiponectin role in obesity and obesity-related diseases. *Biomed Res Int* 2014 DOI:10.1155/2014/658913.

Niraula, S., Ocana, A., Goodwin, P. (2012). Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. *Breast Cancer Res Treat.*, 134:769-781.

Oger, F., Gheeraert, C., Mogilenko, D., Benomar, Y., Molendi-Coste, O., Bouchaert, E. *et al.* (2014). Cell-specific dysregulation of microRNA expression in obese white adipose tissue. *J Clin Endocrinol Metab.* 99:2821-2833. DOI:10.1210/jc.2013-4259.

Oh, S. W., Park, C., Lee, E.S., Yoo, Y.S., Lee, E.S, Park, S.S. *et al.* (2011). Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study. *Breast Cancer Research*, 13(2). DOI: 10.1186/bcr2856.

Ording, A.G., Cronin-Fenton, D.P., Jacobsen, J.B., Noordgard, M., Thomsen, R.W. (2013). Comorbidity and survival of Danish breast cancer patients from 2000–2011: a population-based cohort study. *Clinical Epidemiology*; 5 (Suppl 1): 39–46.

Ortega, F.J., Moreno-Navarrete, J.M., Pardo, G., Sabater, M., Hummel, M., Ferrer, A. *et al.* (2010) MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. *PLoS One.* 2;5: e9022. DOI:10.1371/journal.pone.0009022.

Osaki, Y., Taniguchi, S., Tahara, A., Okamoto, M., Kishimoto, T. (2012). Metabolic syndrome and incidence of liver and breast cancers in Japan. *Cancer Epidemiology* 36:141-147.

Oyamada, M., Takebe, K., Oyamada, Y. (2012). Regulation of connexin expression by transcription factors and epigenetics mechanisms (modifikasi gambar). *Biophysica Acta* 1828/ DOI: 10.1016/j.bbamem.2011.12.031

Paik, H-J., Lee, S.K., Ryu, J.M., Park, S., Kim, I., Bae, S.Y. *et al.* (2017). Conditional disease-free survival among patients with breast cancer. *Medicine.* 96;1: e(5746). DOI: 10.1097/MD00005746.

Pan, H., Guo. J., Su, Z. (2014). Advances in understanding the inter-relations between leptin resistance and obesity. *Physiol Behav.*, 130: 157–169

Park, B., Kong, S., Lee, E.K., Lee, M.H., Lee, E.S. (2017). Metabolic syndrome in breast cancer survivors with high carbohydrate consumption: The first report in community setting. *Clin Nutr.* 36:1372-1377.

Pasanisi, P., Berrino, F., De Petris, M., Venturelli, E., Mastroianni, A., Panico, S. (2006). Metabolic syndrome as risk factor for breast cancer recurrences. *Int J Cancer.* 119:236-238



UNIVERSITAS
GADJAH MADA

HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA SUB-TIPE MOLEKULER HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin, miR-222-3p, dan miR-143-3p
KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM
Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Peng, Y., Yu, S., Li, H., Xiang, H., Peng, J., Jiang, S. (2014). Emerging role in adipogenesis and obesity. *Cell Signal*. DOI:10.1016/j.cellsig.2014.05.006

Phung, M.T., Tin, S.T., Elwood, J.M. 2019. Prognostic models for breast cancer: a systematic review. *BMC Cancer*. 19:230. DOI: 10.1186/s12885-019-5442-6

Porto, L.A., Lora, K.J., Soares, J.C., Costa, L.O. (2011). Metabolic syndrome is an independent risk factor for breast cancer. *Arch Gynecol Obstetr*. 284; 5: 1271-1276.

Qin, L., Chen, Y., Niu, Y., Chen, W., Wang, Q., Xiao, S. *et al.* (2010). A deep investigation into the adipogenesis mechanism: Profile of microRNAs regulating adipogenesis by modulating the canonical Wnt/ β -catenin signaling pathway. *BMC Genomics*.11:320.

Redig, A.J., Munshi, H.G. (2010). Care of the cancer survivor: metabolic syndrome following hormone-modifying therapy. *Am J Med*.123:87-97.

Revegnini G., Cargnin, S., Sammarini, G., Zanotti, F., Bermejo, J.L., Hrelia, P. *et al.* (2019). Prognostic role of miR-221 and miR-22 expression in cancer patients: a systematic review and meta-analysis. *Cancer* 11: 970 DOI:10.3390/cancers1107/0970

Revellion, F., Charlier, M., Lhotellier, V., Hornez, L., Giard, S., Baranzelli, M-C. (2006). Messenger RNA Expression of Leptin and Leptin Receptors and their Prognostic Value in 322 Human Primary Breast Cancers. *Clin Cancer Res*. 12: 2088-2094

Rzepiel, A., Kutszegi, N., Gézsi, A., Sági, J. C., Egyed, B., Péter, G. *et al.* (2019). Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia. *Journal of translational medicine*, 17(1), 372. DOI:10.1186/s12967-019-2114-x

Sadeghzadeh, S., Dehghani Ashkezari, M., Seifati, S. M., Vahidi Mehrjardi, M. Y., Dehghan Tezerjani, M., Sadeghzadeh, S., & Ladan, S. (2020). Circulating miR-15a and miR-222 as Potential Biomarkers of Type 2 Diabetes. *Diabetes, metabolic syndrome and obesity: targets and therapy*.13, 3461–3469. DOI:10.2147/DMSO.S26388.

Sarkar, S., Ghosh, A., Banerjee, S., Maity, G., Das, A., Larson, M. A., Gupta, V., Haque, I., Tawfik, O., Banerjee, S. K. (2017). CCN5/WISP-2 restores ER- α in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen. *Oncogenesis*, 6(5), e340. DOI: 10.1038/oncsis.2017.43.

Saleh, K., Carton, M., Dieras, V., Heudel, P.E., Brain, E., D'Hondt, V. *et al.* (2021). Impact of body mass index on overall survival in patients with metastatic breast cancer. *Breast*. 55:16–24.

Sato, F., Tsuchiya, S., Meltzer, S.J., Shimizu, K. (2011). MicroRNAs and Epigenetics. *FEBS* 278:1598-1609.

Santorelli, M.L., Hirschfield, K.M., Steinberg, M.B., Lin, Y., Rhoads, G.G., Bandera, E.V. *et al.* (2017). Racial differences in the effect of comorbidity on breast cancer-specific survival. *Cancer Causes Control*.28: 809-817.



UNIVERSITAS
GADJAH MADA

HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA SUB-TIPE MOLEKULER HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin, miR-222-3p, dan miR-143-3p
KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM
Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Schech, A., Yu, S., Goloubeva, O., McLenthian, J., Sabnis, G. (2015). A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitor. *Endocr.-Relat.o Cancer* 22:645-656

Schmidt, S., Monk, J.L., Robinson, L.E., Mourtszakakis, M. (2015). The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise. *Obesity reviews* 16:473-487.

Schoenfeld, D.A. 1983. Sample size formula for proportional hazard-regression model. *Biometrics* 39:499-503

Shah, M. Y., & Calin, G. A. (2011). MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. *Genome medicine*, 3(8), 56. DOI:10.1186/gm272

Shahril, M.R., Amirfaiz, S., Lua, P.L., Nurnazahiah, A., Zakarai, N.S., Kow, V.L. *et al.* (2021). Prevalence of metabolic syndrome among breast cancer survivor in East Coast of Peninsular Malaysia. *BMC Public Health*; 21: 238 [Epub] DOI.org/10.1186/s12889-021010288-9

Shen, H., Wang, D., Li, L., Yang, S., Chen, X. Zhou, S. *et al.* (2017). miR-222 promote drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. *Gene*.596: 110-118.

Simon, M.S., Beebe-Dimmer, J.L., Hastert, T.A., Manson, J.A.E., Cespedes Feliciano, E.M., Neuhausser, M.L. *et al.* (2018). Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. *Cancer*. 124:1798-1807

Song, Q., An, Q., Niu, B., Lu, X., Zhang, N., Chao, X. (2019). Role of miR-221/222 in tumor development and the underlying mechanisms. *Journal of Oncology*. DOI:10.1155/2019/7252013

Sorlie, T., Perou, C.M., Tibshirani, R. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci* 98: 10869–10874.

Specht, K., Harbeck, N., Smida, J., Annecke, K., Reich, U., Naehrig, J. (2008). Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. *Breast Cancer Res and Treat*. 118: 45-56. DOI:10.1007/s10549-008-0207-y

Stienstra, R., Duval, C., Müller, M., Kersten, S. (2007). PPARs, obesity, and inflammation. *PPAR research*, 95974. DOI:10.1155/2007/95974

Stinson, S., Lackner, M.R., Adai, A.T., Yu, N., Kim, H., Spoerke, J. *et al.* (2011). TRPS1 targeting by miR-221/222 promotes the epithelial-to mesenchymal transition in breast cancer. *Sci Signal* 4: ra41 DOI:10.1126/scisignal.2001538

Sun, X., Nichols, H.B., Robinson, W., Sherman, M.E., Olshan, A.F. (2015). Post diagnosis adiposity and survival among breast cancer patients: influence of breast cancer sub-type. *Cancer Cause Control*. 26:1803-1811

Oh, S. W. *et al.* (2011) 'Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study', *Breast Cancer Research*, 13(2). doi: 10.1186/bcr2856.



UNIVERSITAS
GADJAH MADA

HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA SUB-TIPE MOLEKULER HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin, miR-222-3p, dan miR-143-3p
KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM
Universitas Gadjah Mada, 2021 | Diunduh dari <http://eud.repository.ugm.ac.id/>

Suzuki, T., Hayashi, S., Miki, Y., Nakamura, Y., Moriya, T., Sugawara, A. *et al.* (2006). Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. *Endocr Relat Cancer*. 13: 233–250. DOI:10.1677/erc.1.01075

Tang, T., Yang, Z., Zhu, Q., Wu, Y., Sun, K., Alahdal, M. *et al.* (2018). Up-regulation of miR-210 induced by a hypoxic microenvironment promotes breast cancer stem cells metastasis, proliferation, and self-renewal by targeting E-cadherin. *FASEB J*. fj201801013R. DOI:10.1096/fj.201801013R

Teoh, S.L., Das, S. (2016). Tumor biology of obesity-related cancers: understandings the molecular concept for better diagnosis and treatment. *Tumor Biol*. 31: 14363-14380 DOI:10.1007/s13277-016-5357-7.

Testa, U., Castelli, G., Pelosi, E. 2020. Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments. *Med Sci (Basel)* :18. DOI : 10.3390/medsci8010018.

Tchernof, A., Despres, J.P. (2013). Pathophysiology of human visceral obesity. *Physiol Rev*. 93:359-404

Tokumaru, Y., Asaoka, M., Oshi, M., Katsuta, E., Yan, L., Narayanan, S. *et al.* (2020). High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer. *Int. J. Mol. Sci*. 21:3213. DOI:10.3390/ijms21093213

Tryggvadottir, H., Rodstrom, M.Y., Markkula, A., Kenez, X., Borgquist, K., Jernstrom, H. (2019). The impact of body mass changes on recurrence risk depends on age and estrogen receptor status in primary breast cancer. *Cancer Causes & Control*. 30:1157-1170

Wang, D.D., Yang, S.J., Chen, X., Shen, H.Y., Luo, L.J., Zhang, X.H. *et al.* (2016). miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27kip1 pathway. *Tumour Biol*. 37:15315-15324.

Wang, D., Sang, Y., Sun, T., Kong, P., Zhang, L., Dai, Y. *et al.* (2021). Emerging roles and mechanisms of microRNA-222-3p in human cancer. *International journal of oncology*, 58(5), 20. DOI:0.3892/ijo.2021.5200

Wang, M., Li, L., Liu, R., Song, Y., Zhang, X., Niu, W. *et al.* (2018) Obesity-induced overexpression of miRNA-24 regulates cholesterol uptake and lipid metabolism by targeting SR-B1. *Gene*. 668:196-203

Wang, X., Sun, Y., Wong, J., Conklin, D. S. (2013). PPAR γ maintains ERBB2-positive breast cancer stem cells. *Oncogene*. 32: 5512–5521. DOI:10.1038/onc.2013.217

Withers, S., Dewhurst, T., Hammond, C., Topham, C.H. (2020). miRNAs as novel adipokines: obesity-related circulating miRNAs influence chemosensitivity in cancer patients. *Non-Coding RNA*. 6:5; DOI:10.3390/ncrna6010005.



UNIVERSITAS
GADJAH MADA

HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA SUB-TIPE MOLEKULER HR+/HER2- NON-METASTATIK Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin, miR-222-3p, dan miR-143-3p
KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM
Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Wu, C-E., Chen S-C., Chang, H-K., Lo, Y-F., Hsueh, S., Lin, Y-C. (2016). Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years. *JFMA*. 115:249-256.

Wu, Q., Sun, S., Li, Z., Yang, Q., Li, B., Zhu, S. *et al.* (2019). Breast cancer-released exosomes trigger cancer-associated cachexia to promote tumor progression. *Adipocyte* 8: 31–45. DOI:10.1080/21623945.2018.1551688

Wu, Y., Luo, Q., Li, X., Arshad, B., Xu, Z., Ran, L. *et al.* (2018). Clinical study on the prevalence among Chinese breast cancer women and control population. *J Cancer*. 9:548-555

Xia, C., Yang, Y., Kong, F., Kong, Q., Shan, C. (2018). MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7. *Biochimie* 147: 98-104

Oh, S. W. *et al.* (2011) ‘Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study’, *Breast Cancer Research*, 13(2). doi: 10.1186/bcr2856.

Yang, Z., Chen, D., Nie J. (2016). MicroRNA-143 targets CD44 to inhibit breast cancer progression and stem cell-like properties. *Molecular Medicine Report* 13: 5193-5199

Zhai L., Ma, C., Li, W. (2016). Mir-143 suppresses epithelial-mesenchyma; transition and inhibits tumor growth of breast cancer through down regulation of ERK5. *Molecular Carcinogenesis*. 55:1990-2000. DOI:10.1002/mc.22445

Zhang, H. L., Wang, X. X., Zhang, F. (2019). Correlations of the MiR-330 expression with the pathogenesis and prognosis of breast cancer. *European review for medical and pharmacological sciences*. 23: 1584–1590. DOI:10.26355/eurrev-201902-17117

Zhang, J., Kong, X., Shi, Q., Zhao, B. (2020). MicroRNA-383-5p acts as a potential prognostic biomarker and an inhibitor of tumor cell proliferation, migration, and invasion in breast cancer. *Cancer biomarkers: section A of Disease markers*, 27: 423–432. DOI:10.3233/CBM-190704

Zhang, M., Cai, H., Bao, P., Xu, W., Qin, G., Shu, X. (2017). Body mass index, waist-to-hip ratio and late outcomes: a report from the Shanghai Breast Cancer Survival Study. *Scientific Report*.7:6996. [Epub]. DOI:10.1038/s41598-017-07320-7

Zhang, P., Du, J., Wang, L., Niu, L., Zhao, Y., Tang, G. *et al.* (2018). MicroRNA-143a-3p modulates preadipocyte proliferation and differentiation by targeting MAPK7. *Biomed Pharmacother*.108: 531–539.DOI:10.1016/j.biopha.2018.09.080

Zhang, P., Zhang, M., Han, R., Zhang, K., Ding, H.,Liang, C. *et al.* (2018). The correlation between microRNA-221/222 cluster overexpression and malignancy: an updated meta-analysis including 2693 patients. *Cancer Manag and Res*. 10:3371-3381

Zhang, S., Wang, Y., Wang, Y., Peng, J., Yuan, W., Zhou, I. *et al.* (2020). Serum miR-222-3p as a double-edged sword in predicting efficacy and trastuzumab-induced cardiotoxicity for HER2-positive breast cancer patients receiving neoadjuvant target therapy. *Front Oncol*. DOI:10.3389/fonc.2020.00631



UNIVERSITAS
GADJAH MADA

**HUBUNGAN SINDROMA METABOLIK, OBESITAS, DAN KESINTASAN PASIEN KANKER PAYUDARA
SUB-TIPE MOLEKULER
HR+/HER2- NON-METASTATIK** Kajian pada Biomarka Metabolik, Mitogenik, dan Epigenetik: Leptin,
miR-222-3p, dan miR-143-3p

KARTIKA WIDAYATI, Prof.Dr.dr. Teguh Aryandono, SpB.(K).Onk; dr. Mardiah S. Hardianti, PhD., SpPD-KHOM

Universitas Gadjah Mada, 2021 | Diunduh dari <http://ejd.repository.ugm.ac.id/>

Zhang, W., Chen, C.J., Guo, G.L. (2018). MiR-155 promotes the proliferation and migration of breast cancer cells via targeting SOCS1 and MMP16. *Eur Rev Med Pharmacol Sci.* 22:7323-7332

Zhang. Y., Yan, J., Wang, L, Dai, H., Li, N., Hu, W. *et al.* (2017). HIF-1 α Promotes Breast Cancer Cell MCF-7 Proliferation and Invasion Through Regulating miR-210. *Cancer Biother Radiopharm.*32:297-301

Zhao, J.J., Lin, J., Yang, H., Kong, W., He, L., Ma, X. *et al.* (2008). MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. *J Biol Chem*; 283:31079–86.

Zheng, T., Zhang, X., Wang, Y., Yu, C. (2016). Predicting associations between microRNAs and target genes in breast cancer by bioinformatics analyses. *Oncology Letters* 12:1067-1073

Zhou, L.L., Dong, J.L., Huang, G., Sun, J.L., Wu, J. (2017). MicroRNA-143 inhibits cell growth by targeting ERK5 and MAP3K7 in breast cancer. *Braz J Med Biol Res.*, 50: e5891, DOI:10.1590/1414-431X20175891.

Zhou, X., Wang, X., Huang, Z., Xu, L., Zhu, W., Liu, P. (2014). An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer. *J Exp Clin Cancer Res* 33:1-6 DOI:10.1186/s13046-014-0094-5

Zhou, Y., Liu, M, Li, J., Wu, B., Tian, W., Shi, L. *et al.* (2018). The inverted pattern of circulating miR-221-3p and miR-222-3p associated with isolated low HDL-C phenotype. *Lipids Health Dis.* 17:1888 DOI:10.1186/s12944-018-0842-1

Zhu, Q., Xu, W., Tao, M. (2010). Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis. *Cancers* 2:721-729

Zong, Y., Zhang, Y., Sun, X., Xu, T., Cheng, X., Qin, Y. (2019). miR-221/222 promote tumor growth and suppress apoptosis by targeting lncRNA GAS5 in breast cancer. *Biosci Rep.* 39: BSR20181859.